NCT05767931

Development of Multi-specific Antibodies Based on Immune Microenvironment of Breast Cancer

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 60 (estimated)
• Sponsor: Peking University · Academic / Other
• Sex: Female
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, single-center, non-randomized, non-controlled study

Detailed description

Immunotherapy with immune-checkpoint inhibitors (ICIs) has enabled a leap forward in the treatment of various types of cancer within the past decade. However,only 12.46% of patients with cancer are expected to respond to ICIs.Our team have recently developed a multi-specific antibody technology platform for the microenvironment of solid tumors. In this study, we are going to study the tumor immune microenvironment of breast cancer patients by patient-derived organoids or PDX model，to design multi-specific antibody drugs for different tumor immune microenvironment，to look forward to improve the effectiveness of immunotherapy for breast cancer and solve the problem of drug resistance.

Conditions

• Invasive Breast Cancer

Timeline

• Start date: 2023-03-06
• Primary completion: 2024-11-06
• Completion: 2025-03-06
• First posted: 2023-03-14
• Last updated: 2023-03-14

Locations

1 site across 1 country: China